Overview
- Quest reported first-quarter revenue of $2.895 billion, a 9.2 percent increase from a year earlier, as organic revenue grew 9 percent.
- Total test orders rose 10.9 percent, with relationships with Fresenius Medical Care and Corewell Health contributing about 7 percentage points to organic growth.
- Adjusted operating income reached $447 million for a 15.4 percent margin, and adjusted diluted EPS rose about 13 percent on productivity from automation and AI across operations.
- Management raised its 2026 guidance to $11.78–$11.90 billion in sales and $10.63–$10.83 in adjusted EPS following the strong quarter.
- Shares gained about 5 percent in afternoon trading, with investors responding to momentum in consumer health, advanced diagnostics like Alzheimer’s and cardiometabolic tests, and an active M&A pipeline.